Drug Approval | December 12, 2025
Bristol Myers Squibb scores FDA priority review for Opdivo in advanced hodgkin lymphoma
The FDA aims to make a decision by April 8, 2026
The FDA aims to make a decision by April 8, 2026
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Akero became a wholly owned subsidiary of Novo Nordisk
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The launch of the study was on the occasion of the International Day of Persons with Disabilities
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
Subscribe To Our Newsletter & Stay Updated
